Top Tweets for #KEYNOTE057
π‘ A study from @AndreaNecchi and colleagues analyzed cohort B of the phase 2 #KEYNOTE057 trial in which patients with #BCG-unresponsive high-risk #NMIBC and papillary tumors without #CIS received #pembrolizumab #monotherapy.
π Read More: https://t.co/8p2AtEpLWx
Pembrolizumab's impact on cystectomy-free survival in BCG unresponsive #BladderCancer from #KEYNOTE057. @GSK_UofT @UofT and @UroDocAsh @MDAndersonNews discuss these promising results and the importance of timely cystectomy to prevent metastatic disease > https://t.co/y646XcpufD
Results from cohort B of the phase 2 #KEYNOTE057 trial, pembrolizumab monotherapy for patients with high-risk #NMIBC unresponsive to BCG. @AndreaNecchi @SanRaffaeleMI joins @CaPsurvivorship @DanaFarber in this discussion on UroToday > https://t.co/aN8kZqw7BA
Pembrolizumab's impact on cystectomy-free survival in BCG unresponsive #BladderCancer from #KEYNOTE057. @GSK_UofT @UofT and @UroDocAsh @MDAndersonNews discuss these promising results and the importance of timely cystectomy to prevent metastatic disease > https://t.co/y646XcpufD
Results from cohort B of the phase 2 #KEYNOTE057 trial, pembrolizumab monotherapy for patients with high-risk #NMIBC unresponsive to BCG. @AndreaNecchi @SanRaffaeleMI joins @CaPsurvivorship @DanaFarber in this discussion on UroToday > https://t.co/aN8kZqw7BA
Pembrolizumab's impact on cystectomy-free survival in BCG unresponsive #BladderCancer from #KEYNOTE057. @GSK_UofT @UofT and @UroDocAsh @MDAndersonNews discuss these promising results and the importance of timely cystectomy to prevent metastatic disease > https://t.co/y646XcpufD
Pembrolizumab for patients with high-risk #NMIBC unresponsive to BCG: Efficacy and evaluation of subsequent cystectomy from Cohort B of phase 2 #KEYNOTE057 study. Presented by @eric_facs @OSU_Urology. #AUA23 coverage by @RuchikaTalwarMD > https://t.co/sXZTZyHJfX #BladderCancer
Extended follow-up results of #CheckMate274 and results of pembrolizumab monotherapy in BCG-unresponsive HR #NMIBC: findings from cohort B of #KEYNOTE057. Join Michiel Van der Heijden, PhD @NKI_nl and @CaPsurvivorship @DanaFarber on UroToday > https://t.co/8FY6IuKpKh
Results from cohort B of the phase 2 #KEYNOTE057 trial, pembrolizumab monotherapy for patients with high-risk #NMIBC unresponsive to BCG. @AndreaNecchi @SanRaffaeleMI joins @CaPsurvivorship @DanaFarber in this discussion on UroToday > https://t.co/aN8kZqw7BA
Pembrolizumab monotherapy for pts with high-risk #NMIBC unresponsive to BCG: Results from cohort B of the phase 2 #KEYNOTE057 trial. Presented by Michiel Van Der Heijden, MD, PhD @NKI_nl. @ASCO #GU23 written coverage by @WallisCJD @UofT > https://t.co/ZyiuZrDv1X
Pembrolizumab monotherapy for pts with high-risk nonmuscle-invasive #BladderCancer unresponsive to BCG: Results from cohort B of the phase 2 #KEYNOTE057 trial. Presented by @AndreaNecchi @SanRaffaeleMI. @ASCO #GU23 written coverage by @WallisCJD > https://t.co/j7oozIUcLt
Phase 2 #KEYNOTE057 Cohort C: Pembrolizumab with vibostolimab or favezelimab for pts with high-risk BCG-unresponsive #NMIBC. Presented by Neal D. Shore, MD, FACS @AtlanticUrology. @ASCO #GU23 written coverage by @WallisCJD @UofT > https://t.co/nWmG4bzL6S
Phase 2 #KEYNOTE057 Cohort C: Pembrolizumab with vibostolimab or favezelimab for pts with high-risk BCG-unresponsive #NMIBC. Presented by Neal D. Shore, MD, FACS @AtlanticUrology. @ASCO #GU23 written coverage by @WallisCJD @UofT > https://t.co/nWmG4bzL6S
#GU23 Stellar presentation by @AndreaNecchi
Pembro mono for pts w/ HR NMIBC unresponsive to BCG shows impressive efficacy regardless of baseline characteristics
π’Stable/improved QoL in >70% of ptsπ’
#KEYNOTE057
@OncoAlert
Don't miss, #GU23 presentation by @AndreaNecchi @SanRaffaeleMI on the results of cohort B of the phase 2 #KEYNOTE057 trial. We're looking forward to seeing all the great work being presnted at this year's @ASCO #GU annual meeting! #StayTuned for live coverage on UroToday!
Do not miss the #GU23 Oral Abstract Session B - Urothelial carcinoma on Friday Feb 17. Plenty of new data from early to late stages & great discussants #Keynote057 #IMvigor130 #CheckMate274 @MattGalsky @apolo_andrea Aris Bamias Michiel VdHejiden @ASCO @MyUniSR @SanRaffaeleMI
Pembrolizumab in the real-world setting for nonmuscle-invasive #BladderCancer unresponsive to #BCG. @ArjunBalarMD @nyulangone joins @PGrivasMDPhD @UW for a discussion on UroToday > https://t.co/29rxyQXKUD @fredhutch @SeattleCCA #KEYNOTE057
Pembrolizumab in the real-world setting for nonmuscle-invasive #BladderCancer unresponsive to #BCG. @ArjunBalarMD @nyulangone joins @PGrivasMDPhD @UW for a discussion on UroToday > https://t.co/29rxyQXKUD @fredhutch @SeattleCCA #KEYNOTE057
Pembrolizumab in the real-world setting for nonmuscle-invasive #BladderCancer unresponsive to #BCG. @ArjunBalarMD @nyulangone joins @PGrivasMDPhD @UW for a discussion on UroToday > https://t.co/29rxyQXKUD @fredhutch @SeattleCCA #KEYNOTE057
Pembrolizumab for the treatment of patients with high-risk #NMIBC unresponsive to BCG: extended follow-up of #KEYNOTE057 Cohort A. Presentation by @ArjunBalarMD @nyulangone. #GU21 written coverage by @zklaassen_md @gacancercenter > https://t.co/X4uc55vogJ @ASCO #ASCOGU
Last Seen Hashtags on Sotwe
ΰΈ₯ΰΈ²ΰΈΰΈΰΈ£ΰΉΰΈ²ΰΈ§
Seen from Thailand
goth
Seen from Argentina
str8bait
Seen from United States
ΰΈΰΉΰΈΰΉΰΈ’ΰΉΰΈΰΈ₯ΰΈΉΰΈ
Seen from Singapore
omegle
Seen from United Kingdom
momson()*********************
Seen from Pakistan
BeberSozinho
Seen from United States
teenage follow
Seen from Belgium
AceiteDePalma
Seen from United States
lyon
Seen from United States
Most Popular Users
Elon Musk 
@elonmusk
241.5M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
113.9M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.6M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.7M followers
KATY PERRY
@katyperry
89.7M followers
Taylor Swift
@taylorswift13
83.6M followers
Lady Gaga
@ladygaga
75.1M followers
Virat Kohli
@imvkohli
72.9M followers
Kim Kardashian
@kimkardashian
70.7M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
65.9M followers
Bill Gates
@billgates
64.9M followers
Selena Gomez
@selenagomez
62.8M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers